Brain accumulation of the amyloid-β (Aβ) peptide is believed to be the initial event in the
Alzheimer disease (AD) process. Aβ accumulation begins 15–20 years before clinical …

Considerable overlap has been identified in the risk factors, comorbidities and putative
pathophysiological mechanisms of Alzheimer disease and related dementias (ADRDs) and …

The amyloid-β oligomer (AβO) hypothesis was introduced in 1998. It proposed that the brain
damage leading to Alzheimer's disease (AD) was instigated by soluble, ligand-like AβOs …

Energy demand of neurons in brain that is covered by glucose supply from the blood is
ensured by glucose transporters in capillaries and brain cells. In brain, the facilitative …

Despite the significant public health issue that it poses, only five medical treatments have
been approved for Alzheimer's disease (AD) and these act to control symptoms rather than …

The increasing cost of drug development together with a significant drop in the number of
new drug approvals raises the need for innovative approaches for target identification and …

In the last decade, much attention has been devoted to the effects of nutrient-related signals
on brain development and cognitive functions. A turning point was the discovery that brain …

Clinical studies suggest a link between type 2 diabetes mellitus (T2DM) and insulin
resistance (IR) and cognitive dysfunction, but there are significant gaps in our knowledge of …

Abstract Alzheimer's Disease (AD), the most prevalent neurodegenerative disease of aging,
affects one in eight older Americans. Nearly all drug treatments tested for AD today have …

Cross-talk between adipose tissue and central nervous system (CNS) underlies the
increased risk of obese people to develop brain diseases such as cognitive and mood …